Patents by Inventor Cynthia A. Cowgill
Cynthia A. Cowgill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7851433Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).Type: GrantFiled: January 8, 2004Date of Patent: December 14, 2010Assignees: Novartis Vaccines and Diagnostics, Inc., Pharmacia & Upjohn CompanyInventors: David H. Reifsnyder, Duane Inlow, Glenn Dorin, Patricio T. Riquelme, Cynthia A. Cowgill, Douglas G. Bolesch, Mark E. Gustafson
-
Patent number: 7193042Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: June 7, 1995Date of Patent: March 20, 2007Assignees: Chiron Corporation, Cephalon, Inc.Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
-
Patent number: 7071313Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: May 2, 2000Date of Patent: July 4, 2006Assignees: Cephalon, Inc., Chiron CorporationInventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D Kudrna, Asuman G. Ozturk, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
-
Publication number: 20050037475Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).Type: ApplicationFiled: January 8, 2004Publication date: February 17, 2005Applicants: Chiron Corporation, Pharmacia & Upjohn CompanyInventors: David Reifsnyder, Duane Inlow, Glenn Dorin, Patricio Riquelme, Cynthia Cowgill, Douglas Bolesch, Mark Gustafson
-
Patent number: 6756484Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.Type: GrantFiled: July 12, 2000Date of Patent: June 29, 2004Assignees: Cephalon, Inc., Chiron CorporationInventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka, Cynthia Cowgill, Luis G. Juarbe-Osorio, Patricio Riquelme, Glenn Dorin
-
Patent number: 6322779Abstract: The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.Type: GrantFiled: June 7, 1995Date of Patent: November 27, 2001Assignee: Chiron CorporationInventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 6117983Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: December 15, 1997Date of Patent: September 12, 2000Assignee: Chiron CorporationInventors: Cynthia Cowgill, Louis Juarbe, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Ausman G. Otzurk
-
Patent number: 5861150Abstract: The present invention is directed to a biologically active CSF-1 dimer comprising a first CSF-1 monomer and a second CSF-1 monomer, wherein at least one of the monomers is truncated at the C-terminus after residue position 223. The dimers also include point mutations in one or both of the CSF-1 monomer. The invention also includes pharmaceutical compositions that comprise the CSF-1 dimer in a pharmaceutical excipient.Type: GrantFiled: June 7, 1995Date of Patent: January 19, 1999Assignee: Chiron CorporationInventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 5651963Abstract: The present invention relates to the production of CSF-1 heterodimers and pharmaceutical formulations of the heterodimers. The heterodimers can be formed using CSF-1 monomers that have variations in sequence, N or C-terminal processing. For example, CSF/C.gradient.150 can be dimerized with LCSF/C.gradient. 190 to form a heterodimer. Dimerization may occur by separately preparing homodimers and mixing them together under the appropriate conditions. Thereafter, homodimers may be separated from the heterodimers by various chromatographic techniques. Once the heterodimers are isolated, pharmaceutical preparations can be prepared.Type: GrantFiled: November 4, 1994Date of Patent: July 29, 1997Assignee: Chiron CorporationInventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 5466781Abstract: A process is described for producing M-CSF from bacteria. It includes: fermentation of bacteria containing M-CSF DNA; harvest of the fractions that contain the M-CSF protein (refractile bodies); primary recovery of the protein; solubilization and denaturation of refractile bodies; M-CSF refolding; purification by column chromatography and other methods; and formulation of the properly refolded M-CSF. This method is advantageous over prior methods in terms of yield and purity.Type: GrantFiled: March 8, 1993Date of Patent: November 14, 1995Assignee: Chiron TherapeuticsInventors: Glenn Dorin, David R. Gray, Byeong S. Chang, Cynthia A. Cowgill, Robert J. Milley
-
Patent number: 4929700Abstract: A process for recovering dimeric, biologically active CSF-1 from bacterially expressed recombinant CSF1 genes is described. The process comprises recovery of the solubilized monomeric form, followed by dimerization under refolding conditions and further purification of the dimer. Heterodimers may also be produced by this process.Type: GrantFiled: April 8, 1988Date of Patent: May 29, 1990Assignee: Cetus CorporationInventors: Robert Halenbeck, Kriston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 4795806Abstract: Affinity purification of Factor VIII:C, both plasma derived and genetically engineered, using coupled phosphatidylserine (PS) as the predominant phospholipid (PH) results in a high degree of purity of Factor VIII:C, similar to that previously demonstrated with monoclonal antibodies specific to either Factor VIII:C or von Willebrand factor. Phospholipids that can be used in combination with PS are phosphatidycholine (PC) and phosphatidylethanolamine (PE).Type: GrantFiled: July 16, 1987Date of Patent: January 3, 1989Assignee: Miles Laboratories, Inc.Inventors: James E. Brown, Cynthia A. Cowgill